Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. [electronic resource]
Producer: 20160413Description: 2338-46 p. digitalISSN:- 1476-5551
- Aged
- Aged, 80 and over
- Bortezomib -- administration & dosage
- Drug Therapy, Combination
- Everolimus -- administration & dosage
- Female
- Humans
- Male
- Middle Aged
- Mutation
- Myeloid Differentiation Factor 88 -- genetics
- Receptors, CXCR4 -- genetics
- Recurrence
- Rituximab -- administration & dosage
- Waldenstrom Macroglobulinemia -- drug therapy
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.